Table 2.
Major outcomes for the whole COVID-19 cohort, and for the non-hospitalisation, hospitalisation, ITU admission, and encephalopathy cohorts during the illness
| All patients | Patients without hospitalisation | Patients with hospitalisation | Patients with ITU admission | Patients with encephalopathy | |
|---|---|---|---|---|---|
| Intracranial haemorrhage (any) | 0·56% (0·50–0·63) | 0·31% (0·25–0·39) | 1·31% (1·14–1·52) | 2·66% (2·24–3·16) | 3·61% (2·97–4·39) |
| Intracranial haemorrhage (first) | 0·28% (0·23–0·33) | 0·14% (0·10–0·20) | 0·63% (0·50–0·80) | 1·05% (0·79–1·40) | 1·19% (0·82–1·70) |
| Ischaemic stroke (any) | 2·10% (1·97–2·23) | 1·33% (1·22–1·46) | 4·38% (4·05–4·74) | 6·92% (6·17–7·76) | 9·35% (8·23–10·62) |
| Ischaemic stroke (first) | 0·76% (0·68–0·85) | 0·43% (0·36–0·52) | 1·60% (1·37–1·86) | 2·82% (2·29–3·47) | 3·28% (2·51–4·27) |
| Parkinsonism | 0·11% (0·08–0·14) | 0·07% (0·05–0·12) | 0·20% (0·15–0·28) | 0·26% (0·15–0·45) | 0·46% (0·28–0·78) |
| Guillain-Barré syndrome | 0·08% (0·06–0·11) | 0·05% (0·03–0·07) | 0·22% (0·15–0·32) | 0·33% (0·21–0·54) | 0·48% (0·20–1·14) |
| Nerve, nerve root, or plexus disorders | 2·85% (2·69–3·03) | 2·69% (2·51–2·89) | 3·35% (3·02–3·72) | 4·24% (3·58–5·03) | 4·69% (3·81–5·77) |
| Myoneural junction or muscle disease | 0·45% (0·40–0·52) | 0·16% (0·12–0·20) | 1·24% (1·05–1·46) | 3·35% (2·76–4·05) | 3·27% (2·54–4·21) |
| Encephalitis | 0·10% (0·08–0·13) | 0·05% (0·03–0·08) | 0·24% (0·17–0·33) | 0·35% (0·19–0·64) | 0·64% (0·39–1·07) |
| Dementia | 0·67% (0·59–0·75) | 0·35% (0·29–0·43) | 1·46% (1·26–1·71) | 1·74% (1·31–2·30) | 4·72% (3·80–5·85) |
| Mood, anxiety, or psychotic disorder (any) | 23·98% (23·58–24·38) | 23·59% (23·12–24·07) | 24·50% (23·76–25·26) | 27·78% (26·33–29·29) | 36·25% (34·16–38·43) |
| Mood, anxiety, or psychotic disorder (first) | 8·63% (8·28–8·98) | 8·15% (7·75–8·57) | 8·85% (8·22–9·52) | 12·68% (11·28–14·24) | 12·96% (11·13–15·07) |
| Mood disorder (any) | 13·66% (13·35–13·99) | 13·10% (12·73–13·47) | 14·69% (14·09–15·32) | 15·43% (14·27–16·68) | 22·52% (20·71–24·47) |
| Mood disorder (first) | 4·22% (3·99–4·47) | 3·86% (3·60–4·14) | 4·49% (4·05–4·99) | 5·82% (4·86–6·97) | 8·07% (6·56–9·90) |
| Anxiety disorder (any) | 17·39% (17·04–17·74) | 17·51% (17·09–17·93) | 16·40% (15·76–17·06) | 19·15% (17·90–20·48) | 22·43% (20·65–24·34) |
| Anxiety disorder (first) | 7·11% (6·82–7·41) | 6·81% (6·47–7·16) | 6·91% (6·38–7·47) | 9·79% (8·65–11·06) | 9·24% (7·70–11·07) |
| Psychotic disorder (any) | 1·40% (1·30–1·51) | 0·93% (0·83–1·04) | 2·89% (2·62–3·18) | 2·77% (2·31–3·33) | 7·00% (6·01–8·14) |
| Psychotic disorder (first) | 0·42% (0·36–0·49) | 0·25% (0·19–0·33) | 0·89% (0·72–1·09) | 0·70% (0·46–1·06) | 2·12% (1·53–2·94) |
| Substance use disorder (any) | 6·58% (6·36–6·80) | 5·87% (5·63–6·13) | 8·56% (8·10–9·04) | 10·14% (9·25–11·10) | 11·85% (10·55–13·31) |
| Substance use disorder (first) | 1·92% (1·77–2·07) | 1·74% (1·58–1·91) | 2·09% (1·82–2·40) | 3·15% (2·60–3·82) | 2·58% (1·91–3·47) |
| Insomnia (any) | 5·42% (5·20–5·64) | 5·16% (4·91–5·42) | 5·95% (5·53–6·39) | 7·50% (6·66–8·44) | 9·82% (8·57–11·24) |
| Insomnia (first) | 2·53% (2·37–2·71) | 2·23% (2·05–2·43) | 3·14% (2·81–3·51) | 4·24% (3·55–5·07) | 5·05% (4·10–6·20) |
| Any outcome | 33·62% (33·17–34·07) | 31·74% (31·22–32·27) | 38·73% (37·87–39·60) | 46·42% (44·78–48·09) | 62·34% (60·14–64·55) |
| Any first outcome | 12·84% (12·36–13·33) | 11·51% (10·98–12·07) | 15·29% (14·32–16·33) | 25·79% (23·50–28·25) | 31·13% (27·29–35·36) |
Data are percentage at 6 months (95% CI). Additional outcomes are presented in the appendix (pp 27–28). ITU=intensive therapy unit.